NCT01576367View on ClinicalTrials.gov

Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

January 16, 2012

Primary Completion Date

October 13, 2015

Study Completion Date

October 13, 2015

Conditions
Cryopyrin-associated Periodic SyndromesFamilial Cold Autoinflammatory SyndromeMuckle-Wells SyndromeNeonatal Onset Multisystem Inflammatory Disease
Interventions
BIOLOGICAL

ACZ885

Trial Locations (12)

1011

Novartis Investigative Site, Lausanne

1020

Novartis Investigative Site, Laken

1200

Novartis Investigative Site, Brussels

13353

Novartis Investigative Site, Berlin

18012

Novartis Investigative Site, Granada

46026

Novartis Investigative Site, Valencia

53757

Novartis Investigative Site, Saint Augustin

72076

Novartis Investigative Site, Tübingen

94275

Novartis Investigative Site, Le Kremlin-Bicêtre

M5G 1X8

Novartis Investigative Site, Toronto

01307

Novartis Investigative Site, Dresden

WC1N 1EH

Novartis Investigative Site, London

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY